The DEA includes a cannabidiol-based medicine in the Controlled Substances Act

On Thursday 27th of September, Epidiolex became the first cannabidiol-based substance placed under Schedule V of the Controlled Substances Act (CSA) by the Department of Justice and Drug Enforcement Administration (DEA). This was the consequence of a large, controlled and successful clinical trial that led the DEA to accept the medical application of this CBD-based [...]